Abbott Laboratories (ABT)
35.03USD
1 Jul 2013
$0.15 (+0.43%)
$34.88
$34.97
$35.47
$34.90
6,347,902
7,140,543
$72.47
$31.64
ABT
About
Overall
| Beta: | 0.35 |
| Market Cap (Mil.): | $54,607.03 |
| Shares Outstanding (Mil.): | 1,558.86 |
| Dividend: | 0.14 |
| Yield (%): | 1.60 |
Financials
| ABT | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 71.63 | 32.92 | 33.02 |
| EPS (TTM): | 0.49 | -- | -- |
| ROI: | 1.99 | 19.76 | 19.07 |
| ROE: | 3.22 | 20.57 | 20.00 |
Abbvie says Chief Scientific Officer John Leonard to retire
- AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.
Abbvie says Chief Scientific Officer John Leonard to retire
May 10 - AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.
UPDATE 1-Russia rejects Abbott Laboratories' plan to buy Petrovax
MOSCOW, April 19 - Russia's government commission on foreign investment has turned down U.S. group Abbott Laboratories' request to buy Russian vaccine maker Petrovax, the head of Russia's competition regulator said on Friday.
Russia rejects Abbott Laboratories' plan to buy Petrovax
MOSCOW - Russia's government commission on foreign investment has rejected U.S. Abbott Laboratories' plan to buy Russian pharmaceutical producer Petrovax, the head of the Russian antitrust regulator said on Friday.
Russia rejects Abbott Laboratories' plan to buy Petrovax
MOSCOW, April 19 - Russia's government commission on foreign investment has rejected U.S. Abbott Laboratories' plan to buy Russian pharmaceutical producer Petrovax, the head of the Russian antitrust regulator said on Friday.
Abbott hits mark, but devices, generics struggle
- Abbott Laboratories on Wednesday reported higher quarterly earnings after splitting off its branded drug business, and the company said demand was strong for its infant formulas and diagnostic products.
UPDATE 2-Abbott hits mark, but devices, generics struggle
April 17 - Abbott Laboratories on Wednesday reported higher quarterly earnings after splitting off its branded drug business, and the company said demand was strong for its infant formulas and diagnostic products.
FDA advisers vote for approval of Abbott's implantable heart device
- A slim majority of advisers to the U.S. Food and Drug Administration voted on Wednesday for approval of Abbott Laboratories' implantable heart device MitraClip, saying it had more benefits than risks.
FDA advisers vote for approval of Abbott's implantable heart device
March 20 - A slim majority of advisers to the U.S. Food and Drug Administration voted on Wednesday for approval of Abbott Laboratories' implantable heart device MitraClip, saying it had more benefits than risks.
FDA staff does not recommend approval of Abbott's heart device
- Staff reviewers for the Food and Drug Administration did not recommend the approval of Abbott Laboratories' implantable heart device MitraClip, citing a lack of "valid scientific evidence" of safety and effectiveness.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $86.63 | +0.77 |
| Pfizer Inc. (PFE.N) | $27.78 | -0.23 |
| GlaxoSmithKline plc (GSK.L) | 1,664.00p | +5.50 |
| Novartis AG (NOVN.VX) | CHF67.20 | -0.10 |
| Eli Lilly & Co. (LLY.N) | $50.16 | +1.04 |
| Merck & Co., Inc. (MRK.N) | $46.32 | -0.13 |
| AstraZeneca plc (AZN.L) | 3,162.50p | +11.50 |
| Sanofi SA (SASY.PA) | €79.50 | -0.37 |
| Amgen, Inc. (AMGN.OQ) | $97.49 | -1.17 |
| Angiotech Pharmaceuticals, Inc. (USA) (ANPMF.PK) | $25.00 | +8.25 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (ABT). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
